Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.
Sotac Pharmaceuticals's operating assets for the quarter that ended in Sep. 2025 was ₹1,210.7 Mil. Sotac Pharmaceuticals's operating liabilities for the quarter that ended in Sep. 2025 was ₹240.3 Mil. Sotac Pharmaceuticals's Total Assets for the quarter that ended in Mar. 2025 was ₹1,243.3 Mil. Therefore, Sotac Pharmaceuticals's scaled net operating assets (SNOA) for the quarter that ended in Sep. 2025 was 0.78.
Sotac Pharmaceuticals Scaled Net Operating Assets Related Terms
Sotac Pharmaceuticals Scaled Net Operating Assets Historical Data
* Premium members only.
The historical data trend for Sotac Pharmaceuticals's Scaled Net Operating Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sotac Pharmaceuticals Scaled Net Operating Assets Chart
NSE:SOTAC vs ZTS, UTHR: Scaled Net Operating Assets Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Sotac Pharmaceuticals's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sotac Pharmaceuticals Scaled Net Operating Assets vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sotac Pharmaceuticals's Scaled Net Operating Assets distribution charts can be found below:
* The bar in red indicates where Sotac Pharmaceuticals's Scaled Net Operating Assets falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Scaled Net Operating Assets of 0.78 mean?
Sotac Pharmaceuticals (NSE:SOTAC) has a Scaled Net Operating Assets of 0.78 as of Sep. 2025. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Sotac Pharmaceuticals and its competitors.
Is Sotac Pharmaceuticals' Scaled Net Operating Assets too high?
Sotac Pharmaceuticals' current Scaled Net Operating Assets is 0.78. Overall, Sotac Pharmaceuticals has a GF Score™ of 55/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Sotac Pharmaceuticals' Scaled Net Operating Assets compare to ZTS and UTHR?
Sotac Pharmaceuticals' Scaled Net Operating Assets of 0.78 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Scaled Net Operating Assets for a Drug Manufacturers company?
A good Scaled Net Operating Assets depends on the Drug Manufacturers industry context. However, Scaled Net Operating Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Scaled Net Operating Assets mean?
A high Scaled Net Operating Assets can signal that a stock is expensive relative to its fundamentals. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Sotac Pharmaceuticals and its competitors. Sotac Pharmaceuticals's current Scaled Net Operating Assets is 0.78. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sotac Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Sotac Pharmaceuticals (NSE:SOTAC) is currently considered Fairly Valued. The stock's GF Value™ is ₹110.01, compared to a current price of ₹101.00 — trading 8.2% below its estimated fair value. The current Scaled Net Operating Assets is 0.78. Sotac Pharmaceuticals' overall GF Score™ is 55/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Scaled Net Operating Assets calculated?
Scaled Net Operating Assets is calculated from a company's financial statements. For Sotac Pharmaceuticals (NSE:SOTAC), the current Scaled Net Operating Assets is 0.78 as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sotac Pharmaceuticals (NSE:SOTAC) Overvalued in 2026?
Based on GuruFocus' analysis, Sotac Pharmaceuticals stock appears to be undervalued.
The current stock price of ₹101.00 is trading 8.2% below its estimated GF Value™ of ₹110.01.
GuruFocus considers Sotac Pharmaceuticals to be Fairly Valued.
Key valuation signals for NSE:SOTAC:
Scaled Net Operating Assets: 0.78
GF Value™: ₹110.01 vs. price of ₹101.00 (8.2% below fair value)
No single metric tells the full story. See the NSE:SOTAC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sotac Pharmaceuticals Ltd operates chiefly in pharmaceutical manufacturing, serving a broad range of therapeutic segments including anti-diabetic, anti-psychotic, vitamins and minerals, anti-cold, anti-allergic, derma products, antacids, anti-ulcerants, cardiac, analgesic, anti-bacterial, anti-fungal, and more. The company manufactures tablets, capsules, syrups, and external preparations under contract manufacturing and loan licensing agreements, for domestic and international markets. Its clients include notable pharmaceutical marketers such as Cadila Pharma and Viatris. Revenue is distributed between domestic pharmaceutical product sales and international exports, supporting scalable growth across geographies.
55GF Score
Get the complete analysis for NSE:SOTAC
Scaled Net Operating Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:SOTAC has been successfully added to your 
